AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Goldman Sachs analysts said Europe's strong growth rebound wouldn't be derailed, whatever the outcome from the EU's drug regulator on Thursday.

Why the AstraZeneca Vaccine Suspension Won't Derail Europe's Growth Rebound

AstraZeneca PLC (LON:AZN) is set to hear the EU regulator's decision on the COVID-19 vaccine developed with Oxford University later today. Experts from the European Medicines Agency (EMA) are discussing whether to keep rolling out the jab in the bloc after there were cases of blood clots in people who had received it.

AstraZeneca to hear from EU regulator on COVID-19 vaccine today

Europe's medicines regulator is set to report on the safety of the AstraZeneca COVID-19 vaccine on Thursday, after several countries suspended its use.

Why Goldman says the AstraZeneca vaccine suspension isn't a game changer for growth

Oxford University and drug giant AstraZeneca have found themselves at the heart of European political theatre over the past few weeks. The groups' COVID-19 vaccine has been suspended in more than a dozen European countries after a small number of blood clots, including with "unusual features" such as low platelets, were reported in a few people immunized with AstraZeneca's shot. Vaccine regulators and the World Health Organization (WHO) have said the vaccine is safe — but after Denmark suspended the shot on March 11, country after country followed, saying they would wait on the results of an investigation from the European Medicines Agency (EMA), which is expected to conclude later on Thursday.

The future of AstraZeneca's vaccine rollout hinges on 2 crucial decisions, after a month of suspensions and dose shortages

The country halted the use of AstraZeneca's vaccine after more than a dozen countries in Europe suspended the vaccine due to blood clot concerns.

Indonesia will restart AstraZeneca vaccines when regulators give the go ahead, health minister says

New York, New York--(Newsfile Corp. - March 17, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline.SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...

ROSEN, A RESPECTED LAW FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important March 29 Deadline in Securities Class Action - AZN

"This will require major damage control," Dr. Carlos del Rio, a professor of medicine at the Emory University School of Medicine, told CNBC.

U.S. health experts try to ease Covid vaccine fears as AstraZeneca's shot faces review in Europe

Many European countries ignored the WHO and EU medicines regulator and suspended the shot over fears it causes blood clots.

E.U. Chief Blames AstraZeneca For Floundering Vaccination Drive While Member States Refuse To Use It Against Expert Advice

"Vaccination against COVID-19 will not reduce illness or deaths from other causes," the World Health Organization said.

WHO urges countries to keep using AstraZeneca vaccine as ‘benefits outweigh risks'

Los Angeles, California--(Newsfile Corp. - March 17, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC (NASDAQ: AZN) ("AstraZeneca" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive (the ''Class...

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The latest guidance from the global public health body comes after a raft of European countries announced that they would suspend use of the shot.

WHO recommends AstraZeneca vaccinations continue, says benefits still outweigh risks

At least two European Union countries plan to start using AstraZeneca's coronavirus vaccine again if regulators give the green light this week. France and Italy agreed to “promptly” resume their rollout of the British drugmaker's shot if the European Medicines Agency formally confirms that it's safe to use amid concerns about people who received it.

France, Italy to restart AstraZeneca COVID vaccine shots upon regulators' OK

The EMA will continue to investigate whether AstraZeneca's (AZN) COVID-19 vaccine was the cause of the blood clot events or if these were due to other reasons.

AstraZeneca (AZN) COVID-19 Shot Faces Doubts Over Blood Clots

The World Health Organization said Wednesday that the benefits of AstraZeneca's COVID-19 vaccine still outweigh the risks and it should continue to be administered, after several countries in Europe halted vaccinations over concerns about blood clots. U.S.-listed shares of AstraZeneca were down 1.5% in trading on Wednesday.

WHO says to keep administering AstraZeneca's vaccine

According to a Phase 1b-2 trial published in the New England Journal of Medicine, the two-dose COVID-19 vaccine developed by Oxford University / AstraZeneca Plc (NASDAQ: AZN) was ineffective against mild-to-moderate infections caused due to mutated virus strain in South Africa, dubbed as B.1.351 variant. What Happened: The study was led by scientists at the South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit.

AstraZeneca's COVID-19 Vaccine Has No Efficacy Against South African Virus Strain, Study Shows

Novavax

Pfizer

These COVID Stocks Could Be Hurt by a Global Raw Material Shortage

Will recent troubles weigh on AstraZeneca stock?

Some Countries Suspended AstraZeneca's COVID Vaccine. Here's What Investors Need to Know.

France and Italy say they are ready to quickly restart inoculation programs with the AstraZeneca vaccine if regulators confirm it's still safe to use.

Italy and France ready to restart AstraZeneca vaccinations if regulators give the green light

Alexion Pharma

AstraZeneca stock jumped Tuesday after the company reaffirmed its plan to acquire Alexion Pharmaceuticals in the third quarter, even as more European countries suspended use of its Covid vaccine. The post AstraZeneca Pops On Alexion Buyout Despite Mounting Covid Vaccine Doubt appeared first on Investor's Business Daily.

AstraZeneca Pops On Alexion Buyout Despite Mounting Covid Vaccine Doubt

European Medical Agency (EMA) will release its investigation results on Thursday afternoon into incidents of bleeding, blood clots, and low platelet counts after AstraZeneca Plc's (NASDAQ: AZN) coronavirus vaccine, reports Reuters. What Happened: EMA Executive Director Emer Cooke said there was no indication that the incidents, which she called “very rare”, but that experts were assessing that possibility.

EMA Investigating Coagulation Cases After Several European Countries Pause AZN Shot; Findings Expected This Thursday: Reuters

The European Medicines Agency reiterated its findings as Sweden became the latest country to pause inoculations with the AstraZeneca Covid-19 shot.

EU Regulator Says ‘No Indication' AstraZeneca Vaccine Causes Blood Clots

AstraZeneca PLC (LON:AZN) was upgraded to ‘buy' from ‘hold' by Jefferies as analysts believe pipeline catalysts and new launches should aid recovery of the shares. The US investment bank hiked the target price by 7% to 8850p as the risk-reward is significantly more positive, given the pharma giant's “compelling” growth profile within EU Pharma.

AstraZeneca upgraded to ‘buy' by Jefferies as pipeline should aid recovery of shares

Shares in AstraZeneca PLC (LON:AZN) got a boost on Tuesday as the coronavirus (COVID-19) vaccine developed with Oxford University will be reviewed by experts worldwide. The World Health Organization (WHO) and the European Medicines Agency (EMA) will hold separate meetings after 11 EU countries halted the rollout of the jab, alongside Thailand, Venezuela and Indonesia.

AstraZeneca COVID-19 vaccine to be reviewed by WHO, EU regulator

AstraZeneca shares could gain at least another 25% as upcoming COVID-19 vaccine data should provide a buying opportunity, says Jefferies, which also foresees the strategic merits of the drug maker's pending acquisition of Alexion Pharmaceuticals become more "widely appreciated". AstraZeneca's "impressive revenue and profit trajectory is compelling" relative to its European pharmaceutical industry peers, said Jefferies in a research note Tuesday in which it raised its rating to buy from hold. The price target was also increased, to $61.50 from $56.

AstraZeneca stock holds 26% upside on 'multitude of pipeline catalysts', says Jefferies

The European Medicines Agency is "firmly convinced" the vaccine's benefits outweighed the risk of side effects.

News for AstraZeneca Stock (AZN)